ESCRS - PO056 - Tamoxifen Induces Major Topographical Changes Mimicking Post-Lasik Ectasia

Tamoxifen Induces Major Topographical Changes Mimicking Post-Lasik Ectasia

Published 2022 - 40th Congress of the ESCRS

Reference: PO056 | Type: Case report | DOI: 10.82333/7ctf-ma52

Authors: Nanji Lu* 1 , Mark Hillen 1 , Marco Langenegger 2 , David Goldblum 3 , Tamer Tandogan 2 , Farhad Hafezi 1

1ELZA Institute,Zurich,Switzerland, 2Augenklinik, Pallas Kliniken,Olten,Switzerland, 3University Basel,Basel,Switzerland

To report a patient who developed major topographical changes mimicking post-laser in situ keratomileusis (LASIK) ectasia during breast cancer treatment.

ELZA Institute, Dietikon, Switzerland

A 36-year-old woman who had had 10 years of stable vision after laser in situ keratomileusis (LASIK) surgery was diagnosed with breast cancer 6 months before presentation. As therapy, the patient received tamoxifen, a selective estrogen receptor modulator (SERM). After the initiation of therapy, the patient experienced continuously decreasing vision in her left eye. Assessment of corneal tomography led to the diagnosis of postoperative ectasia in the left eye. After 3 months of treatment with tamoxifen, the anterior cornea showed marked flattening and uncorrected distance visual acuity (UDVA) improved to 16/20.

 
Serum estrogen level changes during breast cancer treatment may induce major topographical changes, mimicking postoperative ectasia after LASIK.